Published papers
Atuka’s scientists have been publishing groundbreaking neuroscience research for many decades, often in collaboration with other renowned leaders in our field. The peer-reviewed papers collected below track the evolution of both our ongoing research and the field more broadly.
- 214
- papers
- 1991–2026
- years of publication
- 75
- journals
- 14,017
- citations recorded by Crossref
-
A small molecule reduces both parkinsonism and l -dopa–induced dyskinesia in animal models of Parkinson’s disease
-
Roles of astrocytic Connexin 43 gap junctional deficit in alpha-synucleinopathy and inflammation relevant to Parkinson’s
-
Low β predicts motor output and cell degeneration in the A53T Parkinson’s disease rat model
-
Deep brain stimulation halts Parkinson’s disease-related immune dysregulation in the brain and peripheral blood
-
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
-
Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease
-
Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease
-
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
-
Alterations in the LRRK2-Rab pathway in urinary extracellular vesicles as Parkinson’s disease and pharmacodynamic biomarkers
-
Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
-
Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson’s disease
-
Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases
-
Special Issue on new therapeutic approaches to Parkinson disease
-
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
-
Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice
-
Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease
-
α-Synuclein–induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms
-
A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson’s disease
-
Exosome markers of LRRK2 kinase inhibition
-
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques
-
The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
-
Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein
-
NYX‐458 Improves Cognitive Performance in a Primate Parkinson’s Disease Model
-
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
-
Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson’s Disease
-
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson’s disease
-
Pridopidine, a clinic‐ready compound, reduces 3,4‐dihydroxyphenylalanine‐induced dyskinesia in Parkinsonian macaques
-
Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?
-
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia
-
Corrigendum to “Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism” [Neurobiol. Dis. 106 (2018) 133–146]
-
A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia
-
Non-steric-zipper models for pathogenic α-synuclein conformers
-
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson’s disease.
-
Reply to “Can STN DBS protect both nigral somata and innervation of the striatum?”
-
Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism
-
Animal models of α-synucleinopathy for Parkinson disease drug development
-
Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson’s disease rat model
-
AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease
-
Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
-
α-Synuclein-Based Animal Models of Parkinson’s Disease: Challenges and Opportunities in a New Era
-
Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury
-
Dopamine Reuptake Inhibitors in Parkinsons Disease: A Review of Nonhuman Primate Studies and Clinical Trials
-
The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque
-
The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells – The potential of JNX1001 as a therapeutic agent
-
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET
-
Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson’s Disease
-
Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats
-
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat
-
Management of impulse control disorders in Parkinson’s disease: Controversies and future approaches
-
Pioglitazone may impair L‐DOPA anti‐parkinsonian efficacy in the MPTP‐lesioned macaque: Results of a pilot study
-
Monoamine Reuptake Inhibitors in Parkinson’s Disease
-
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models
-
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset
-
The Opioid System in Levodopa-Induced Dyskinesia
-
Symptomatic Models of Parkinson’s Disease and L-DOPA-Induced Dyskinesia in Non-human Primates
-
TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque
-
Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
-
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
-
Alternating Hemiplegia of Childhood-Related Neural and Behavioural Phenotypes in Na+,K+-ATPase α3 Missense Mutant Mice
-
RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study
-
Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat
-
Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque
-
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
-
Novel nondopaminergic targets for motor features of Parkinson’s disease: Review of recent trials
-
Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat
-
Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice
-
l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson’s disease
-
The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
-
A critique of available scales and presentation of the non‐human primate dyskinesia rating scale
-
L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson’s Disease
-
L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson’s Disease
-
Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson’s disease
-
Dihydropyridine calcium channel blockers and the progression of parkinsonism
-
A novel MDMA analogue, UWA‐101, that lacks psychoactivity and cytotoxicity, enhances l ‐DOPA benefit in parkinsonian primates
-
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA
-
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
-
5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson’s disease: Bridging the gap between serotonergic and glutamatergic mechanisms
-
The serotonergic system in Parkinson’s disease
-
Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson’s Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?
-
Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson’s Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?
-
Pros and cons of a prion-like pathogenesis in Parkinson’s disease
-
A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease
-
Changes in the mRNA Levels of α2A and α2C Adrenergic Receptors in Rat Models of Parkinson’s Disease and l-DOPA-Induced Dyskinesia
-
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, WhereasS-MDMA Extends Duration of ON-Time
-
The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson’s disease
-
Generation of a model of l-DOPA-induced dyskinesia in two different mouse strains
-
Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson’s Disease Produced by Decreasing Doses of Alpha-Synuclein
-
Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism
-
New Approaches to Therapy
-
Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson’s Disease
-
Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson’s Disease
-
The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
-
Locomotor response to l-DOPA in reserpine-treated rats following central inhibition of aromatic l-amino acid decarboxylase: Further evidence for non-dopaminergic actions of l-DOPA and its metabolites
-
Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson’s disease
-
Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
-
Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human α2-adrenergic and dopaminergic receptors
-
Antidyskinetic actions of amantadine in Parkinson’s disease: are benefits maintained in the long term?
-
Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson’s Disease
-
Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson’s Disease
-
The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future
-
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson’s disease
-
Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson’s Disease
-
Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride
-
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate
-
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson’s disease
-
New insights into the organization of the basal ganglia
-
Serotonin and Parkinson’s disease: On movement, mood, and madness
-
Mechanisms compensating for dopamine loss in early Parkinson disease
-
α1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques
-
α1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques
-
The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson’s disease
-
Non-dopaminergic treatments in development for Parkinson’s disease
-
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats
-
Dietary resveratrol administration increases MnSOD expression and activity in mouse brain
-
Striatal histone modifications in models of levodopa‐induced dyskinesia
-
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP + in mesencephalic neurons and by MPTP in a mouse model of Parkinson’s disease
-
Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson’s disease
-
Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice
-
Parkinson’s disease — opportunities for novel therapeutics to reduce the problems of levodopa therapy
-
High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleus
-
Levodopa‐induced dyskinesias
-
Striatal delta opioid receptor binding in experimental models of Parkinson’s disease and dyskinesia
-
Actions at sites other than D3 receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats
-
Novel pharmacological targets for the treatment of Parkinson’s disease
-
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors
-
Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson’s disease
-
Dopamine Receptor Agonists and Levodopa and Inducing Psychosis-Like Behavior in the MPTP Primate Model of Parkinson Disease
-
A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats
-
Dopamine Receptor Agonists and Levodopa and Inducing Psychosis-Like Behavior in the MPTP Primate Model of Parkinson Disease
-
Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyskinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia
-
Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure
-
Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson’s disease
-
α2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata
-
Advances in the delivery of treatments for Parkinson’s disease
-
Nondopaminergic mechanisms in levodopa‐induced dyskinesia
-
Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus
-
MPTP‐Induced Models of Parkinson’s Disease in Mice and Non‐Human Primates
-
A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson’s disease
-
Subcellular redistribution of the synapse‐associated proteins PSD‐95 and SAP97 in animal models of Parkinson&s disease and L‐DOPA‐induced dyskinesia
-
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease
-
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson’s disease
-
Levodopa-induced dyskinesia in Parkinson?s disease
-
Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson’s disease
-
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson’s disease
-
Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats
-
Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate
-
Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets
-
Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson’s Disease
-
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole
-
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque
-
Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson’s disease: implications for dyskinesia
-
Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson’s disease
-
Cannabinoids Decrease Corticostriatal Synaptic Transmission via an Effect on Glutamate Uptake
-
Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus
-
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson’s disease
-
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset
-
Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson’s disease
-
Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated
-
CB cannabinoid receptor signalling in Parkinson’s disease
-
5‐hydroxytryptamine (5‐HT, serotonin) and Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy
-
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson’s disease
-
Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson’s disease
-
Protection of Striatal Neurons by Joint Blockade of D1 and D2 Receptor Subtypes in an in Vitro Model of Cerebral Hypoxia
-
Striatal AMPA Receptor Binding Is Unaltered in the MPTP-Lesioned Macaque Model of Parkinson’s Disease and Dyskinesia
-
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat
-
Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
-
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
-
Antiparkinsonian Action of a δ Opioid Agonist in Rodent and Primate Models of Parkinson’s Disease
-
Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson’s Disease
-
μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson’s Disease
-
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
-
Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan
-
Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson’s Disease
-
Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys
-
Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson’s disease
-
Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
-
5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson’s disease
-
A Common Signaling Pathway for Striatal NMDA and Adenosine A2aReceptors: Implications for the Treatment of Parkinson’s Disease
-
Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson’s Disease
-
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease
-
5-HT2C receptor antagonists enhance the behavioural response to dopamine D1 receptor agonists in the 6-hydroxydopamine-lesioned rat
-
NMDA receptors in the basal ganglia
-
The adrenergic receptor agonist, clonidine, potentiates the anti‐parkinsonian action of the selective κ‐opioid receptor agonist, enadoline, in the monoamine‐depleted rat
-
The ?2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions ofL-dopa in the MPTP-lesioned primate model of Parkinson’s disease
-
Control of glutamate release by calcium channels and κ‐opioid receptors in rodent and primate striatum
-
Effect of Repeatedl-DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat
-
Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat
-
Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson’s disease
-
[3H]‐2‐Deoxyglucose uptake study in mutant dystonic hamsters: Abnormalities in discrete brain regions of the motor system
-
Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson’s Disease
-
Behavioral Effects of 5-HT2CReceptor Antagonism in the Substantia Nigra Zona Reticulata of the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson’s Disease
-
Topographical Organization of Opioid Peptide Precursor Gene Expression Following Repeated Apomorphine Treatment in the 6-Hydroxydopamine-Lesioned Rat
-
Kappa‐opioid receptor agonists increase locomotor activity in the monoamine‐depleted rat model of parkinsonism
-
The Cannabinoid Receptor Agonist WIN 55,212-2 Reduces D2, but Not D1, Dopamine Receptor-Mediated Alleviation of Akinesia in the Reserpine-Treated Rat Model of Parkinson’s Disease
-
Novel approaches to the symptomatic treatment of parkinsonian syndromes
-
Enhancement of the Behavioral Response to Apomorphine Administration Following Repeated Treatment in the 6-Hydroxydopamine-Lesioned Rat Is Temporally Correlated with a Rise in Striatal Preproenkephalin-B, but Not Preproenkephalin-A, Gene Expression
-
Paradoxical action of the cannabinoid WIN 55,212‐2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
-
Modulation of Neurotransmission by Cannabinoids in the Basal Ganglia
-
Ionotropic glutamate receptors and nitric oxide synthesis in the rat striatum
-
New treatments for movement disorders?
-
Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus
-
Modulation of GABA Transmission by Diazoxide and Cromakalim in the Globus Pallidus: Implications for the Treatment of Parkinson’s Disease
-
Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat
-
Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2
-
Potential of Opioid Antagonists in the Treatment of Levodopa-Induced Dyskinesias in Parkinson??s Disease
-
Modulation of glutamate release by a κ-opioid receptor agonist in rodent and primate striatum
-
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson’s disease
-
Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for treatment of parkinsonian symptoms
-
Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes
-
On the Role of Enkephalin Cotransmission in the GABAergic Striatal Efferents to the Globus Pallidus
-
Chapter 8 Chemical signalling in the globus pallidus in parkinsonism
-
d-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents
-
Modeling the functional organization of the basal ganglia. A parallel distributed processing approach
-
Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate
No papers match these filters.
Talk to our experts
